Cytogenetics disclosed 80% abnormal B cells. Fluorescence in situ hybridization results revealed a karyotype of 43XY with monosomy 13 and absence of MYB (myeloblastosis) gene deletion, loss of ATM (ataxia telangiectasia mutated), p53 (protein 53) tumor gene suppression, trisomy 12, and IgH (immunoglobulin heavy locus1) gene rearrangement, which is equal to no abnormality of chromosome 17. This pattern, in general, suggests a favorable prognosis for CLL/SLL. Fluorodeoxyglucose (18F, FDG) scan of several bulky FDG-avid cervical nodes were obtained. Within the subcutaneous soft tissue of the posterior neck, innumerable enlarged bilateral axillary lymph nodes; mediastinal, abdominal, inguinal, and internal and external iliac lymph nodes; cardiophrenic and costophrenic lymph nodes; an intermediate 4-mm right middle lobe pulmonary nodule; and mild splenomegaly demonstrating increased metabolic activity were seen. Positron emission tomographycomputed tomography showed no evidence of malignancy.
The obtained findings gave an initial impression of locally advanced skin cancer, melanoma versus squamous cell carcinoma, but most findings were clinically closer to the appearance of melanoma. The first biopsy was performed using a 3-mm punch biopsy, which failed to confirm the exact histology. Thus, a misdiagnosis of atypical fibroxanthoma was made. Since this lesion was growing despite chemotherapy with bendamustine and rituximab, the diagnosis of the first biopsy was thought to be a sampling error. At this point, surgical extirpation was recommended. After 2 cycles of bendamustine and rituximab, resection of the fungating right neck tumor, right modified radical neck dissection, and right superficial parotidectomy with flap reconstruction were performed.
Histologically, a highly pleomorphic infiltrative neoplasm with vague fascicular pattern that abutted but did not involve the epidermis was observed. The tumor cells were predominantly large, round to rhomboid with abundant eosinophilic cytoplasm and large ovoid vesicular nuclei with prominent irregular nucleoli (Figure 1A). Necrosis with a mitotic rate of approximately 5/10 in high-power fields was identified. Immunohistochemistry revealed tumor cells to be strongly and diffusely positive for desmin and caldesmon. CD68 was positive within intratumoral macrophages. The tumor cells showed weak cytoplasmic positivity for S100, but were negative for cytokeratin AE1/3, AMA, CD34, tyrosinase, HMB45, and Melan A (Figure 1b). These findings supported the diagnosis of LMS.
The tumor size in greatest dimension was 12.0 cm, followed by an additional dimension of 7.0 cm. The final pathological diagnosis was high-grade LMS of the skin and the subcutaneous tissue with invasion into the skeletal muscle, as well as metastatic LMS in multiple lymph nodes. The LMS metastasized to multiple lymph nodes that were also involved with CLL/SLL (Figure 2A-C). The mitotic rate was 5/10 in high-power fields. There was no macroscopic necrosis but microscopic necrosis was present in 15% of the nodes. The grade was set to be 3 according to the French Federation of Cancer Centers Sarcoma Group. The pathologic staging was pT2a, pN1 (3+/15) Mx, G3. The margin was uninvolved by sarcoma, and the closest margin was 0.1 cm.
Few cases of synchronous lymph node involvement of different kinds of tumors concomitant with lymphoproliferative disorders or other malignancies have been reported in the literatüre[5-9]. Most of them involve CLL/SLL and different kinds of cancers such as cutaneous malignant neoplasm expressing the Langerhans cell phenotype, dendritic cell tumor, malignant melanoma, oropharyngeal squamous cell carcinoma, colon carcinoma, and squamous cell carcinoma of the uterine cervix[6-8,10-13]. Immunosuppression may predispose CLL/SLL patients to a high risk of second malignancies[11,14]. Irradiation, alkylating agent chemotherapy, and antimetabolite use have been identified as risk factors that potentiate second malignancies[15,16]. The monoclonal antibody rituximab has been previously linked to second malignancies[17,18], and rituximab was one of the medications of our patient. Congyang et al. reported a case of synchronous histiocytic sarcoma (HS) and diffuse large B cell lymphoma (DLBL) involving the stomach[19]. According to immunohistochemical results of their study; HS and DLBL co-expressed Oct-2, Bcl-2, and Bcl-6, they suggest that HS may share a common origin with DLBL, or be transdifferentiated from DLBL[19]. Bonetti et al. described two distinctive malignancies, cutaneous neoplasm and chronic lymphocytic leukemia, in a single lymph node at the inguinal region[8]. Demellawy et al. reported a case of synchronous malignant melanoma and CLL/SLL in the same lymph node[20]. To our knowledge, this is the first report of cutaneous LMS and CLL/SLL existing synchronously at the same lymph nodes.
Accurate diagnosis and histological classification with adequate sampling is critical for treating soft tissue tumors as cytological and architectural features may be inadequate to distinguish the different sarcomas, particularly if they are poorly differentiated. In the present case, the initial clinical impression was locally advanced skin cancer, leading to a misdiagnosis of atypical fibroxanthoma based on punch biopsy. The correct final diagnosis was made after wide surgical excision and lymph node dissection.
In conclusion, we reported here our encounter with a case of synchronous occurrence of three rare phenomena: soft tissue sarcoma presenting as LMS, involvement of the head and neck region and the metastasis of the leiomyosarcoma to the same lymph node affected by lymphoma.
1) Robbins Basic Pathology. In: Kumar V, Abbas AK, Fausto N,
Mitchell RN, editors. 8th ed. Soft tissue tumors. Elsevier; 2007.
837.
2) Sumida T, Hamakawa H, Otsuka K, Tanioka H. Leiomyosarcoma
of the maxillary sinus with cervical lymph node metastasis. J Oral
Maxillofac Surg. 2001;59:568-71.
3) Skoulakis C, Chimona TS, Tsirevelou P, Papadakis CE.
Subcutaneus leiomyosarcoma of the neck: A case report. Cases J.
2010;3:52.
4) Murray F Brennan, Kaled M Alektiar, Robert G. Cancer;
Principles and practice of oncology. In: Devita VT, Hellman S,
Rosenberg SA, editors. Soft tissue sarcoma. 6th ed. Lippincott
Williams & Wilkins; 2001.1841-91.
5) Cossu A, Deiana A, Lissia A, Dedola MF, Cocco L, Palmieri G,
Tanda F. Synchronous interdigitating dendritic cell sarcoma
and B-cell small lymphocytic lymphoma in a lymph node. Arch
Pathol Lab Med. 2000;130:544-7.
6) McElroy C, Velilla R, Chaudhary H, Al-Abbadi MA. Fine-needle
aspiration diagnosis of squamous cell carcinoma in a lymph node
involved with small lymphocytic lymphoma: Case report and
review of the literature. Diagn Cytopathol. 2009;37:48-50.
7) Quilon JM, Day S, Lasker JC. Synchronous tumors: Hodgkin
disease presenting in mesenteric lymph nodes from a right
hemicolectomy for colon carcinoma. South Med J. 2004;97:1133-5.
8) Bonetti F, Knowles DM 2nd, Chilosi M, Pisa R, Fiaccavento S,
Rizzuto N, Zamboni G, Menestrina F, Fiore-Donati L. A distinctive
cutaneous malignant neoplasm expressing the Langerhans cell
phenotype. Synchronous occurrence with B-chronic lymphocytic
leukemia. Cancer. 1985;55:2417-25.
9) Vasef MA, Zaatari GS, Chan WC, Sun NC, Weiss LM, Brynes
RK. Dendritic cell tumors associated with low-grade B-cell
malignancies. Report of three cases. Am J Clin Pathol.
1995;104:696-701.
10) Flezar MS, Prevodnik VK, Kirbis IS, Strojan P. Cutaneous
squamous cell carcinoma metastatic to chronic lymphocytic
leukaemia: Diagnostic potential of fine needle aspiration cytology.
Cytopathology. 2006;17:288-294.
11) Mehrany K, Weenig RH, Lee KK, Pittelkow MR, Otley CC.
Increased metastasis and mortality from cutaneous squamous
cell carcinoma in patients with chronic lymphocytic leukemia. J
Am Acad Dermatol. 2005;53:1067-71.
12) Mikami Y, Maehata K, Fujiwara K, Sasano H. Squamous cell
carcinoma of the uterine cervix in association with stage 0
chronic lymphocytic leukemia/small lymphocytic lymphoma.
Gynecol Oncol. 2004;92:974-7.
13) Amamoo DG, Moayeri H, Takita H, Han T. Bronchogenic
carcinoma in chronic lymphocytic leukemia. Chest. 1979;75:
174-7.
14) Koreishi AF, Saenz AJ, Arcila ME, Hedvat C, Fleming S, Teruya-
Feldstein J. Synchronous Follicular Lymphoma, Kaposi Sarcoma,
and Castleman's Disease in a HIV-negative patient with EBV and
HHV-8 coinfection. Int J Surg Pathol. 2011;19:685-91.
15) Ng AK, Travis LB. Subsequent malignant neoplasms in cancer
survivors. Cancer J. 2008;14:429-34.
16) Renard M, Suciu S, Bertrand Y, Uyttebroeck A, Ferster A,
van der Werff Ten Bosch J, Mazingue F, Plouvier E, Robert A,
Boutard P, Millot F, Munzer M, Mechinaud F, Lescoeur B, Baila L,
Vandecruys E, Benoit Y, Philippet P; EORTC Children Leukaemia
Group (CLG) Second neoplasm in children treated in EORTC
58881 trial for acute lymphoblastic malignancies: Low incidence
of CNS tumours. Pediatr Blood Cancer. 2011;57:119-25.
17) Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A,
Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V,
Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, Di Nicola
M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A. Risk factors
for the development of secondary malignancy after high-dose
chemotherapy and autograft, with or without rituximab: A 20-
year retrospective follow-up study in patients with lymphoma. J
Clin Oncol. 2011;29:814-24.
18) Aksoy S, Arslan C, Harputluoglu H, Dizdar O, Altundag K.
Malignancies after rituximab treatment: Just coincidence or
more? J BUON. 2011;16:112-5.